{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:20:10Z","timestamp":1794918010095,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sunshine Coast Hospital and Health Service Study Education Research Trust Fund (SERTF) and Wishlist","award":["Clinician Researcher Fellowship"],"award-info":[{"award-number":["Clinician Researcher Fellowship"]}]},{"name":"Australian National Health and Medical Research Council","award":["APP2007007"],"award-info":[{"award-number":["APP2007007"]}]},{"name":"Advancing Queensland Clinical Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In recent years, numerous dosing studies have been conducted to optimize therapeutic antibiotic exposures in patients with serious infections. These studies have led to the inclusion of dose optimization recommendations in international clinical practice guidelines. The last international survey describing dosing, administration and monitoring of commonly prescribed antibiotics for critically ill patients was published in 2015 (ADMIN-ICU 2015). This study aimed to describe the evolution of practice since this time.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional international survey distributed through professional societies and networks was used to obtain information on practices used in the dosing, administration and monitoring of vancomycin, piperacillin\/tazobactam, meropenem and aminoglycosides.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 538 respondents (71% physicians and 29% pharmacists) from 409 hospitals in 45 countries completed the survey. Vancomycin was mostly administered as an intermittent infusion, and loading doses were used by 74% of respondents with 25\u00a0mg\/kg and 20\u00a0mg\/kg the most favoured doses for intermittent and continuous infusions, respectively. Piperacillin\/tazobactam and meropenem were most frequently administered as an extended infusion (42% and 51%, respectively). Therapeutic drug monitoring was undertaken by 90%, 82%, 43%, and 39% of respondents for vancomycin, aminoglycosides, piperacillin\/tazobactam, and meropenem, respectively, and was more frequently performed in high-income countries. Respondents rarely used dosing software to guide therapy in clinical practice and was most frequently used with vancomycin (11%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We observed numerous changes in practice since the ADMIN-ICU 2015 survey was conducted. Beta-lactams are more commonly administered as extended infusions, and therapeutic drug monitoring use has increased, which align with emerging evidence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-023-04527-1","type":"journal-article","created":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T23:09:32Z","timestamp":1687129772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["International survey of antibiotic dosing and monitoring in adult intensive care units"],"prefix":"10.1186","volume":"27","author":[{"given":"Paul G.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Tabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menino Osbert","family":"Cotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salmaan","family":"Kanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahand","family":"Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Elhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f2nia","family":"Luque-Pardos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Schellack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National Coordinators on behalf of the European Society of Intensive Care Medicine (ESICM) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients [ESGCIP]","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Koulenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Gurjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmi","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gentle","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cortegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Abidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schellongowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"issue":"15","key":"4527_CR1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","volume":"323","author":"J-L Vincent","year":"2020","unstructured":"Vincent J-L, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323(15):1478\u201387.","journal-title":"JAMA"},{"issue":"11","key":"4527_CR2","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1093\/jac\/dky314","volume":"73","author":"G Wong","year":"2018","unstructured":"Wong G, Briscoe S, McWhinney B, Ally M, Ungerer J, Lipman J, et al. Therapeutic drug monitoring of beta-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother. 2018;73(11):3087\u201394.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4527_CR3","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1186\/cc13874","volume":"18","author":"S Blot","year":"2014","unstructured":"Blot S, Koulenti D, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care (London, England). 2014;18(3):R99.","journal-title":"Crit Care (London, England)"},{"issue":"8","key":"4527_CR4","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current \u00df-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072\u201383.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4527_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","volume":"40","author":"JJ De Waele","year":"2014","unstructured":"De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014;40(3):380\u20137.","journal-title":"Intensive Care Med"},{"issue":"12","key":"4527_CR6","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1128\/AAC.49.12.4920-4927.2005","volume":"49","author":"VH Tam","year":"2005","unstructured":"Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration\/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49(12):4920\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4527_CR7","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.2174\/138920111798808329","volume":"12","author":"JA Roberts","year":"2011","unstructured":"Roberts JA. Using PK\/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol. 2011;12(12):2070\u20139.","journal-title":"Curr Pharm Biotechnol"},{"issue":"4","key":"4527_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","volume":"36","author":"JA Roberts","year":"2010","unstructured":"Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36(4):332\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"4527_CR9","doi-asserted-by":"publisher","first-page":"e01008","DOI":"10.1128\/AAC.01008-18","volume":"62","author":"EL Heil","year":"2018","unstructured":"Heil EL, Nicolau DP, Farkas A, Roberts JA, Thom KA. Pharmacodynamic target attainment for cefepime, meropenem and piperacillin\/tazobactam using a pharmacokinetic\/pharmacodynamic-based dosing calculator in critically ill patients. Antimicrob Agents Chemother. 2018;62:e01008.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"4527_CR10","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/jac\/dkv165","volume":"70","author":"A Tabah","year":"2015","unstructured":"Tabah A, De Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, et al. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother. 2015;70(9):2671\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"4527_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijantimicag.2016.02.017","volume":"47","author":"MO Cotta","year":"2016","unstructured":"Cotta MO, Dulhunty JM, Roberts JA, Myburgh J, Lipman J. Should \u03b2-lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists. Int J Antimicrob Agents. 2016;47(6):436\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"4527_CR12","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/jac\/dkt523","volume":"69","author":"G Wong","year":"2014","unstructured":"Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, et al. An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother. 2014;69(5):1416\u201323.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4527_CR13","first-page":"162","volume":"12","author":"JM Dulhunty","year":"2010","unstructured":"Dulhunty JM, Webb SA, Paterson DL, Bellomo R, Myburgh J, Roberts JA, et al. A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units. Crit Care Resusc J Australas Acad Crit Care Med. 2010;12(3):162\u201370.","journal-title":"Crit Care Resusc J Australas Acad Crit Care Med"},{"issue":"2","key":"4527_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/0310057X1103900212","volume":"39","author":"JM Dulhunty","year":"2011","unstructured":"Dulhunty JM, Paterson D, Webb SAR, Lipman J. Antimicrobial utilisation in 37 Australian and New Zealand intensive care units. Anaesth Intensive Care. 2011;39(2):231\u20137.","journal-title":"Anaesth Intensive Care"},{"issue":"7","key":"4527_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cmi.2016.04.019","volume":"22","author":"A Charmillon","year":"2016","unstructured":"Charmillon A, Novy E, Agrinier N, Leone M, Kimmoun A, Levy B, et al. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for \u03b2-lactam administration and therapeutic drug monitoring among critically ill patients in France. Clin Microbiol Infect. 2016;22(7):625\u201331.","journal-title":"Clin Microbiol Infect"},{"key":"4527_CR16","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1097\/CCM.0000000000005357","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49:1974.","journal-title":"Crit Care Med"},{"issue":"5","key":"4527_CR17","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4527_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127\u201353.","journal-title":"Intensive Care Med"},{"issue":"2","key":"4527_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.018","volume":"55","author":"P Williams","year":"2020","unstructured":"Williams P, Beall G, Cotta MO, Roberts JA. Antimicrobial dosing in critical care: a pragmatic adult dosing nomogram. Int J Antimicrob Agents. 2020;55(2): 105837.","journal-title":"Int J Antimicrob Agents"},{"key":"4527_CR20","unstructured":"World Bank \"World Bank Country and Lending Groups.\" [Internet]. World Development Indicators, The World Bank Group, 2022. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups. 2022 [cited 13\/04\/2022]."},{"issue":"11","key":"4527_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the Society of infectious diseases pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm"},{"key":"4527_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jcrc.2020.08.027","volume":"60","author":"U Liebchen","year":"2020","unstructured":"Liebchen U, Paal M, Scharf C, Schroeder I, Grabein B, Zander J, et al. The ONTAI study\u2014a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units. J Crit Care. 2020;60:260\u20136.","journal-title":"J Crit Care"},{"issue":"1","key":"4527_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13613-021-00917-2","volume":"11","author":"C Lanckohr","year":"2021","unstructured":"Lanckohr C, Boeing C, De Waele JJ, de Lange DW, Schouten J, Prins M, et al. Antimicrobial stewardship, therapeutic drug monitoring and infection management in the ICU: results from the international A- TEAMICU survey. Ann Intensive Care. 2021;11(1):131.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"4527_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11096-019-00938-9","volume":"42","author":"GJ Barton","year":"2020","unstructured":"Barton GJ, Morecroft CW, Henney NC. A survey of antibiotic administration practices involving patients with sepsis in UK critical care units. Int J Clin Pharm. 2020;42(1):65\u201371.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"4527_CR25","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/pharmaceutics13101577","volume":"13","author":"YV Fuentes","year":"2021","unstructured":"Fuentes YV, Blanco J, D\u00edaz-Quijano DM, Lechtig-Wasserman S, Liebisch-Rey H, D\u00edaz-Pinilla N, et al. Administration and therapeutic drug monitoring of \u03b2-lactams and vancomycin in critical care units in Colombia: the antibiocol study. Pharmaceutics. 2021;13(10):1577.","journal-title":"Pharmaceutics"},{"issue":"2","key":"4527_CR26","doi-asserted-by":"publisher","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","volume":"62","author":"MN Neely","year":"2018","unstructured":"Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62(2):e02042.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4527_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm. 2009;66(1):82\u201398.","journal-title":"Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm"},{"issue":"14","key":"4527_CR28","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/ajhp\/zxab132","volume":"78","author":"CM Bland","year":"2021","unstructured":"Bland CM, Crosby CM, Orvin DL, Smith SE, Jones BM. Transitioning from guideline approval to practical implementation of AUC-based monitoring of vancomycin. Am J Health Syst Pharm. 2021;78(14):1270\u20132.","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"4527_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ijantimicag.2015.01.007","volume":"45","author":"JJ De Waele","year":"2015","unstructured":"De Waele JJ, Lipman J, Carlier M, Roberts JA. Subtleties in practical application of prolonged infusion of \u03b2-lactam antibiotics. Int J Antimicrob Agents. 2015;45(5):461\u20133.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"4527_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","volume":"18","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108\u201320.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4527_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent \u03b2-lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681\u201391.","journal-title":"Am J Respir Crit Care Med"},{"key":"4527_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.584813","volume":"8","author":"J Liu","year":"2021","unstructured":"Liu J, Zhang S, Huang S, Chen Y, Zhang L, Du H, et al. Rationality of time-dependent antimicrobial use in intensive care units in China: a nationwide cross-sectional survey. Front Med (Lausanne). 2021;8: 584813.","journal-title":"Front Med (Lausanne)"},{"key":"4527_CR33","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1093\/jac\/dkac291","volume":"77","author":"P Tritscher","year":"2022","unstructured":"Tritscher P, Delannoy M, Agrinier N, Charmillon A, Degand N, Dellamonica J, et al. Assessment of current practice for \u03b2-lactam therapeutic drug monitoring in French ICUs in 2021: a nationwide cross-sectional survey. J Antimicrob Chemother. 2022;77:2650.","journal-title":"J Antimicrob Chemother"},{"key":"4527_CR34","unstructured":"Mangalore RP, Ashok A, Lee SJ, Romero L, Peel TN, Udy AA, et al. Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis et al. Clin Infect Dis Off Publ Infect Dis Soc Am. 2022."},{"issue":"1","key":"4527_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13613-021-00834-4","volume":"11","author":"C Roger","year":"2021","unstructured":"Roger C, Louart B, Elotmani L, Barton G, Escobar L, Koulenti D, et al. An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Ann Intensive Care. 2021;11(1):49.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"4527_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","volume":"27","author":"DJ Touw","year":"2005","unstructured":"Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit. 2005;27(1):10\u20137.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"4527_CR37","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijantimicag.2017.11.009","volume":"51","author":"S De Winter","year":"2018","unstructured":"De Winter S, Wauters J, Meersseman W, Verhaegen J, Van Wijngaerden E, Peetermans W, et al. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial. Int J Antimicrob Agents. 2018;51(4):562\u201370.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"4527_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","volume":"38","author":"R G\u00e1lvez","year":"2011","unstructured":"G\u00e1lvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents. 2011;38(2):146\u201351.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"4527_CR39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jac\/dkv291","volume":"71","author":"C Roger","year":"2015","unstructured":"Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, et al. Impact of 30 mg\/kg amikacin and 8 mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2015;71(1):208\u201312.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4527_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13613-016-0211-z","volume":"6","author":"N Allou","year":"2016","unstructured":"Allou N, Bouteau A, Allyn J, Snauwaert A, Valance D, Jabot J, et al. Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. Ann Intensive Care. 2016;6(1):106.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"4527_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","volume":"21","author":"NA van Lent-Evers","year":"1999","unstructured":"van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999;21(1):63\u201373.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"4527_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","volume":"155","author":"RD Moore","year":"1987","unstructured":"Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93\u20139.","journal-title":"J Infect Dis"},{"issue":"4","key":"4527_CR43","doi-asserted-by":"publisher","first-page":"R165","DOI":"10.1186\/cc12844","volume":"17","author":"W Duszynska","year":"2013","unstructured":"Duszynska W, Taccone FS, Hurkacz M, Kowalska-Krochmal B, Wiela-Hoje\u0144ska A, K\u00fcbler A. Therapeutic drug monitoring of amikacin in septic patients. Crit Care. 2013;17(4):R165.","journal-title":"Crit Care"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04527-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04527-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04527-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:03:31Z","timestamp":1687133011000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04527-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4527"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04527-1","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Queensland, Human Research Ethics Committee, granted ethics approval and a waiver of consent for the study titled \u2018International Survey on Antibiotic Dosing and Monitoring in Adult ICUs\u2019 on 2nd March 2021 (2020\/HE002747).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}